Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K - GENMAB A/S (0001434265) (Filer)
Regulatory Filings
2026-05-13 English
6-K - GENMAB A/S (0001434265) (Filer)
Regulatory Filings
2026-05-12 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 93% confidence The document is a Company Announcement detailing the terms and effects of a share capital increase following the exercise of employee warrants, including number of new shares, subscription prices, and updated nominal share capital. This is a direct announcement of a change in the company’s capital structure (new share issuance). It does not present a full financial report, earnings release, or AGM materials, nor is it a mere publication notice. It fits the definition of "Share Issue/Capital Change" (Code: SHA).
2026-05-12 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 87% confidence The document is a corporate announcement detailing an increase in share capital resulting from the exercise of employee warrants. It is an announcement of new share issuance/capital change (number of new shares, nominal value, pricing, and registration details). There are no financial statements or regulatory certifications—just a notice of share capital adjustment. This fits the “Share Issue/Capital Change” category (SHA).
2026-05-12 English
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is a notification of major shareholding, detailing the acquisition of voting rights crossing a threshold (5.0783%) in a company (GENMAB A/S). It includes specific data about voting rights, share capital, and the chain of controlled undertakings. This type of document corresponds to a Major Shareholding Notification, which is used to inform regulatory bodies and the market about significant changes in share ownership levels.
2026-05-08 Danish
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is titled 'Major Shareholder Announcement' and references a notification under Section 30 of the Danish Capital Markets Act regarding Orbis Investment Management Limited's voting rights in Genmab A/S. It details the percentage of shares controlled and voting rights, which is typical for a major shareholding notification. The document is short (3916 characters) and focuses solely on the announcement of a change in significant share ownership levels. There is no financial data, report, or other content that would classify it as an annual report, earnings release, or other financial filing. Therefore, the document fits the category of Major Shareholding Notification (MRQ).
2026-05-08 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.